Responsive Image

 

 

Responsive Image

Líneas de investigación:

Trastornos Psicóticos - Epidemiología Clínica y Neurocognición.
Trastornos psicóticos - Factores diagnósticos, pronósticos y terapéuticos.
Consumo de nicotina en trastornos psicóticos - la hipótesis de la automedicación.
Alteraciones cognitivas - en trastornos psicóticos y posibles vías de tratamiento.

Actividades del grupo:

Los trastornos psicóticos son enfermedades mentales de elevada gravedad y cronicidad que afectan aproximadamente al 2,5% de la población, produciendo importantes costes personales y asistenciales.

Los principales objetivos de este equipo son:

Identificar factores pronóstico relevantes que permitan orientar el diseño de intervenciones para mejorar el curso de la enfermedad.

Identificar marcadores endofenotípicos que ayuden a los clínicos a apoyar de forma más fiable un diagnóstico psicótico específico durante las fases tempranas.

Determinar la presencia de un posible factor biológico que explique la alta prevalencia de consumo de tabaco en esta población y orientar intervenciones sobre esta adicción.

Definir el perfil de afectación cognitiva y su evolución tanto en fases tempranas como en pacientes crónicos y valorar la eficacia de la rehabilitación cognitiva como una posible herramienta terapéutica.

Esperamos obtener resultados que además de ofrecer una mayor comprensión sobre los mecanismos de la enfermedad, permitan diseñar nuevas estrategias de intervención destinadas a incrementar la salud y calidad de vida de estos pacientes.

Coordinador/a del grupo:

Integrantes del grupo:

Publicaciones del grupo:

Rivero, G., Muguruza, C., Corzo, V., Meana, J. J., Callado, L. F.. ADRA2A and ADRA2C gene expression in post-mortem brain is differentially upregulated in subjects with major depressive disorder and schizophrenia. Eur. Neuropsychopharmacol.. 2019; 29(1): 40 - 41. FI: 4,468(Q1). DOI: 10.1016/j.euroneuro.2018.11.1012.

Odagaki, Y., Kinoshita, M., Ota, T., Meana, J. J., Callado, L. F., Garcia-Sevilla, J. A.. 5-HT2A receptor- and M1 muscarinic acetyl-choline receptor-mediated Galpha(q) signalling in patients with psychiatric disorders. Eur. Neuropsychopharmacol.. 2019; 29(1): 43 - 44. FI: 4,468(Q1). DOI: 10.1016/j.euroneuro.2018.11.1015.

Brocos Mosquera, I., Erdozain, A. M., Meana, J. J., Callado, L. F., Diez-Alarcia, R.. Alterations in alpha 2A-adrenoceptor mediated G-protein signalling in postmortem prefrontal cortex of schizophrenia subjects. Eur. Neuropsychopharmacol.. 2019; 29(2): 638 - 639. FI: 4,468(Q1). DOI: 10.1016/j.euroneuro.2019.01.011.

Callado, L. F., Ibarra-Lecue, I., Diez-Alarcia, R., Meana, J. J., Uriguen, L.. Decreased ribosomal protein S6 phosphorylation in post-mortem prefrontal cortex of subjects with schizophrenia: Effects of antipsychotic treatment. Eur. Neuropsychopharmacol.. 2019; 29(1): 321 - 321. FI: 4,468(Q1). DOI: 10.1016/j.euroneuro.2018.11.495.

Brocos Mosquera, I., Rivero, G., Morentin, B., Meana, J. J., Callado, L. F.. Histone acetylation and methylation at ADRA2A gene promoter in postmortem prefrontal cortex of subjects with schizophrenia. Eur. Neuropsychopharmacol.. 2019; 29(1): 325 - 326. FI: 4,468(Q1). DOI: 10.1016/j.euroneuro.2018.11.501.

Diez-Alarcia, R., Muguruza, C., Rivero, G., Garcia-Bea, A., Callado, L. F., Martin, A., Llop, J., Meana, J. J.. Human cerebral 5-HT2A receptor labelling with [18F]altanserin, [3H]LSD, and [3H]M100907. Relevance of radiotracer intrinsic activity. Eur. Neuropsychopharmacol.. 2019; 29(1): 324 - 324. FI: 4,468(Q1). DOI: 10.1016/j.euroneuro.2018.11.499.

Prades, R., Munarriz-Cuezva, E., Uriguen, L., Meana, J. J., Tarrago, T.. IPR-166: a potent and selective prolyl oligopeptidase inhibitor ameliorates cognitive symptoms associated to schizophrenia after oral administration. Eur. Neuropsychopharmacol.. 2019; 29(1): 244 - 244. FI: 4,468(Q1). DOI: 10.1016/j.euroneuro.2018.11.390.

Muguruza, C., Palomo-Ruiz, J. L., Morentin, B., Callado, L. F., Gonzalez-Maeso, J., Meana, J. J.. Serotonin 2A receptors in the postmortem prefrontal cortex of suicide victims: the relevance of controlling confounding variables. Eur. Neuropsychopharmacol.. 2019; 29(1): 325 - 325. FI: 4,468(Q1). DOI: 10.1016/j.euroneuro.2018.11.500.

Erdozain, Amaia M., Brocos-Mosquera, Iria, Gabilondo, Ane M., Meana, J. Javier, Callado, Luis F.. Differential alpha(2A)- and alpha(2C)-adrenoceptor protein expression in presynaptic and postsynaptic density fractions of postmortem human prefrontal cortex. J Psychopharmacol. 2019; 33(2): 244 - 249. FI: 4,221(Q1). DOI: 10.1177/0269881118798612.

Salgueiro, Monika, Segarra, Rafael. Long-acting injectable second-generation antipsychotics in first-episode psychosis: a narrative review. Int Clin Psychopharmacol. 2019; 34(2): 51 - 56. FI: 1,638(Q3). DOI: 10.1097/YIC.0000000000000249.

Arango, Celso, Baeza, Inmaculada, Bernardo, Miquel, Canas, Fernando, de Dios, Consuelo, Diaz-Marsa, Marina, Paz Garcia-Portilla, Maria, Gutierrez-Rojas, Luis, Manuel Olivares, Jose, Rico-Villademoros, Fernando, Rodriguez-Jimenez, Roberto, Maria Sanchez-Morla, Eva, Segarra, Rafael, Crespo-Facorro, Benedicto. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. Rev Psiquiatr Salud Ment. 2019; 12(2): 92 - 105. FI: 2,927(Q2). DOI: 10.1016/j.rpsm.2018.03.006.

Neus Fullana, M., Ferres-Coy, Albert, Ortega, Jorge E., Ruiz-Bronchal, Esther, Paz, Veronica, Javier Meana, J., Artigas, Francesc, Bortolozzi, Analia. Selective Knockdown of TASK3 Potassium Channel in Monoamine Neurons: a New Therapeutic Approach for Depression. Mol. Neurobiol.. 2019; 56(4): 3038 - 3052. FI: 4,586(Q1). DOI: 10.1007/s12035-018-1288-1.

Grinan-Ferre, Christian, Vasilopoulou, Foteini, Abas, Sonia, Rodriguez-Arevalo, Sergio, Bagan, Andrea, Sureda, Francesc X., Perez, Belen, Callado, Luis F., Garcia-Sevilla, Jesus A., Julia Garcia-Fuster, M., Escolano, Carmen, Pallas, Merce. Behavioral and Cognitive Improvement Induced by Novel Imidazoline I-2 Receptor Ligands in Female SAMP8 Mice. Neurotherapeutics. 2019; 16(2): 416 - 431. FI: 5,552(Q1). DOI: 10.1007/s13311-018-00681-5.

Mongredien, Raphaele, Erdozain, Amaia M., Dumas, Sylvie, Cutando, Laura, Nunez del Moral, Amaia, Puighermanal, Emma, Amin, Sara Rezai, Giros, Bruno, Valjent, Emmanuel, Javier Meana, J., Gautron, Sophie, Callado, Luis F., Fabre, Veronique, Vialou, Vincent. Cartography of hevin-expressing cells in the adult brain reveals prominent expression in astrocytes and parvalbumin neurons. Brain Struct Funct. 2019; 224(3): 1219 - 1244. FI: 3,622(Q1). DOI: 10.1007/s00429-019-01831-x.

Odagaki, Yuji, Kinoshita, Masakazu, Ota, Toshio, Javier Meana, J., Callado, Luis F., Garcia-Sevilla, Jesus A.. Optimization and pharmacological characterization of receptor-mediated G(i/o) activation in postmortem human prefrontal cortex. Basic Clin Pharmacol Toxicol. 2019; 124(6): 649 - 659. FI: 2,452(Q3). DOI: 10.1111/bcpt.13183.

Morentin Campillo, Benito, Molina Aguilar, Pilar, Monzo Blasco, Ana, Laborda Galvez, Jose Luis, Arrieta Perez, Jon, Sancho Jimenez, Jennifer, Lamas Ruiz, Julia, Lucena Romero, Joaquin. Sudden Death Due to Thoracic Aortic Dissection in Young People: A Multicenter Forensic Study. Rev. Esp. Cardiol.. 2019; 72(7): 553 - 561. FI: 5,126(Q1). DOI: 10.1016/j.rec.2018.07.008.

Morentin, Benito, Callado, Luis F.. Sudden cardiac death associated to substances of abuse and psychotropic drugs consumed by young people: A population study based on forensic autopsies. Drug Alcohol Depend. 2019; 201: 23 - 28. FI: 3,466(Q1). DOI: 10.1016/j.drugalcdep.2019.03.021.

Draminsky Petersen, Hans, Morentin, Benito. Assessing the level of credibility of allegations of physical torture. Forensic Sci.Int.. 2019; 301: 263 - 270. FI: 1,990(Q2). DOI: 10.1016/j.forsciint.2019.05.043.

Muguruza, Carolina, Morentin, Benito, Javier Meana, J., Alexander, Stephen P. H., Callado, Luis F.. Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia. J Psychopharmacol. 2019; 33(9): 1132 - 1140. FI: 4,221(Q1). DOI: 10.1177/0269881119857205.

Alberich S, Fernández-Sevillano J, González-Ortega I, Usall J, Sáenz M, González-Fraile E, González-Pinto A. A systematic review of sex-based differences in effectiveness and adverse effects of clozapine.. Psychiatry Res. 2019; 280: 112506 - 112506. FI: 2,208(Q2). DOI: 10.1016/j.psychres.2019.112506.

Recio-Barbero M, Fuertes-Soriano S, Cabezas-Garduño J, López-Atanes M, Peña-Rotella A, Sáenz-Herrero M. Delayed Diagnosis of an Eating Disorder in a Male Patient With Superior Mesenteric Artery Syndrome: Results From a Case Study.. Front. Psychiatry. 2019; 10: 731 - 731. FI: 3,161(Q2). DOI: 10.3389/fpsyt.2019.00731.

Horrillo, Igor, Ortega, Jorge E., Diez-Alarcia, Rebeca, Uriguen, Leyre, Javier Meana, J.. Chronic fluoxetine reverses the effects of chronic corticosterone treatment on alpha(2)-adrenoceptors in the rat frontal cortex but not locus coeruleus. Neuropharmacology. 2019; 158: 107731 - 107731. FI: 4,367(Q1). DOI: 10.1016/j.neuropharm.2019.107731.

Diez-Alarcia, Rebeca, Yanez-Perez, Victor, Muneta-Arrate, Itziar, Arrasate, Sonia, Lete, Esther, Meana, J. Javier, Gonzalez-Diaz, Humbert. Big Data Challenges Targeting Proteins in GPCR Signaling Pathways; Combining PTML-ChEMBL Models and [(35) S]GTP gamma S Binding Assays. ACS Chem. Neurosci.. 2019; 10(11): 4476 - 4491. FI: 3,861(Q1). DOI: 10.1021/acschemneuro.9b00302.

Ruso-Julve F, Pombero A, Pilar-Cuéllar F, García-Díaz N, Garcia-Lopez R, Juncal-Ruiz M, Castro E, Díaz Á, Vazquez-Bourgón J, García-Blanco A, Garro-Martinez E, Pisonero H, Estirado A, Ayesa-Arriola R, López-Giménez J, Mayor F, Valdizán E, Meana J, Gonzalez-Maeso J, Martínez S, Vaqué JP, Crespo-Facorro B. Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics.. Transl Psychiatry. 2019; 9(1): 306 - 306. FI: 5,182(Q1). DOI: 10.1038/s41398-019-0647-7.

Garcia-Bea, Aintzane, Miranda-Azpiazu, Patricia, Muguruza, Carolina, Marmolejo-Martinez-Artesero, Sara, Diez-Alarcia, Rebeca, Gabilondo, Ane M., Callado, Luis F., Morentin, Benito, Gonzalez-Maeso, Javier, Javier Meana, J.. Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via G(alpha i1)-proteins. Eur. Neuropsychopharmacol.. 2019; 29(12): 1453 - 1463. FI: 4,468(Q1). DOI: 10.1016/j.euroneuro.2019.10.013.

Horrillo, I., Reyes, B. A., Lhamo, T., Meana, J. J., Van Bockstaele, E. J.. Serotonergic 5-HT2A receptors are expressed in noradrenergic locus coeruleus neurons in rats. Eur. Neuropsychopharmacol.. 2019; 29(6): 372 - 373. FI: 4,468(Q1). DOI: 10.1016/j.euroneuro.2019.09.534.

Muneta-Arrate, I., Diez-Alarcia, R., Horrillo, I., Meana, J. J.. Pimavanserin behaves as serotonin 5-HT2A receptor inverse agonist selective for g alpha i/o but not g alpha q/11 proteins in human prefrontal cortex. Eur. Neuropsychopharmacol.. 2019; 29(6): 78 - 79. FI: 4,468(Q1). DOI: 10.1016/j.euroneuro.2019.09.145.

Recio-Barbero, M., Zabala, A., Segarra, R., Santos, B., Ballesteros, F. J.. Cognitive enhancers in schizophrenia: A meta-analysis of Alpha-7 nicotinic acetylcholine receptor agonists for cognitive deficits and negative symptoms. Eur. Neuropsychopharmacol.. 2019; 29(6): 465 - 466. FI: 4,468(Q1). DOI: 10.1016/j.euroneuro.2019.09.657.

Rivero G, Brocos-Mosquera I, Meana JJ, Callado LF. ADRA2A gene expression and epigenetic regulation in postmortem prefrontal cortex of subjects with schizophrenia. Basic Clin. Pharmacol. Toxicol. 2018; 123: 62 - 63. MEETING ABSTRACT.

Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-Sanchez E, Gutierrez-Rojas L, Meana JJ. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review. CNS Drugs. 2018; 32(5): 411 - 420. FI: 4,206(Q1). DOI: 10.1007/s40263-018-0519-3. REVIEW.

Cordero N, Muguruza C, Perez-Palomar B, Munarriz-Cuezva E, Meana JJ, Ortega JE. Behavioural evaluation of a translational animal model of schizophrenia. Basic Clin. Pharmacol. Toxicol.. 2018; 123: 59 - 59. MEETING ABSTRACT.

Brocos-Mosquera I, del Moral AN, Morentin B, Meana JJ, Callado LF, Erdozain AM. Characterisation of spinophilin immunoreactivity in postmortem human brain homogenates. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2018; 81: 236 - 242. FI: 4,185(Q1). DOI: 10.1016/j.pnpbp.2017.09.019.

Ibarra-Lecue I, Mollinedo-Gajate I, Meana JJ, Callado LF, Diez-Alarcia R, Uriguen L. Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway. Neuropsychopharmacology. 2018; 43(10): 2028 - 2035. FI: 6,544(Q1). DOI: 10.1038/s41386-018-0076-y.

Zabala A, Salgueiro M, Saez-Atxukarro O, Ballesteros J, Ruiz-Irastorza G, Segarra R. Cognitive Impairment in Patients With Neuropsychiatric and Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis. J. Int. Neuropsychol. Soc. 2018; 24(6): 629 - 639. FI: 2,777(Q2). DOI: 10.1017/S1355617718000073.

Lopez-Cardona AP, Ibarra-Lecue I, Laguna-Barraza R, Perez-Cerezales S, Uriguen L, Agirregoitia N, et al. Effect of chronic THC administration in the reproductive organs of male mice, spermatozoa and in vitro fertilization. Biochem. Pharmacol. 2018; 157: 294 - 303. FI: 4,235(Q1). DOI: 10.1016/j.bcp.2018.07.045.

Callado LF, Ibarra-Lecue I, Luque-Fernandez V, Meana JJ, Diez-Alarcia R, Uriguen L. Effects of chronic antipsychotics administration on akt-dependent signalling pathways in rat brain cortex. Basic Clin. Pharmacol. Toxicol.. 2018; 123: 58 - 58. MEETING ABSTRACT.

Muneta-Arrate I, Horrillo I, Perez-Palomar B, Martinez-Alberdi L, Ortega JE, Meana JJ. Evaluation of long-term desipramine administration on alpha (2)-adrenoceptors regulating noradrenaline and serotonin release in rat frontal cortex. Basic Clin. Pharmacol. Toxicol. 2018; 123: 59 - 59. MEETING ABSTRACT.

Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, Matsuoka I, et al. Functional coupling between adenosine A(1) receptors and G-proteins in rat and postmortem human brain membranes determined with conventional guanosine-5 '-O-(3-[S-35]thio)triphosphate ([S-35]GTP gamma S) binding or [S-35]GTP gamma S/immunoprecipitation assay. Purinergic Signal. 2018; 14(2): 177 - 190. FI: 3,190(Q2). DOI: 10.1007/s11302-018-9603-x.

Herrero MS. Gender violence and mental health: a gap between clinical assistance and research. Actas Esp Psiquiatr. 2018; 46(1): 31 - 32. FI: 0,878(Q4). LETTER.

Martin-Hernandez D, Caso JR, Meana JJ, Callado LF, Madrigal JLM, Garcia-Bueno B, et al. Intracellular inflammatory and antioxidant pathways in postmortem frontal cortex of subjects with major depression: effect of antidepressants. J. Neuroinflamm. 2018; 15: 251. FI: 5,193(Q1). DOI: 10.1186/s12974-018-1294-2.

Pallas M, Grinan-Ferre C, Abas S, Rodriguez-Arevalo S, Bagan A, Vasilopoulou F, et al. Novel imidazoline i2 receptor ligands for cognitive decline treatment. Basic Clin. Pharmacol. Toxicol. 2018; 123: 54 - 54. MEETING ABSTRACT.

Ordonez-Carrasco JL, Salgueiro M, Sayans-Jimenez P, Blanc-Molina A, Garcia-Leiva JM, Calandre EP, et al. Psychometric properties of the Spanish version of the 12-item Interpersonal Needs Questionnaire in fibromyalgia syndrome patients. An. Psicol. 2018; 34(2): 274 - 282. FI: 0,756(Q4). DOI: 10.6018/analesps.34.2.293101.

Perez-Palomar B, Mollinedo-Gajate I, Berrocoso E, Meana JJ, Ortega JE. Serotonin 5-HT3 receptor antagonism potentiates the antidepressant activity of citalopram. Neuropharmacology. 2018; 133: 491 - 502. FI: 4,249(Q1). DOI: 10.1016/j.neuropharm.2018.02.020.

Brocos-Mosquera I, Gabilondo AM, Meana JJ, Callado LF, Erdozain AM. Spinophilin expression in postmortem prefrontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Basic Clin. Pharmacol. Toxicol. 2018; 123: 59 - 59. MEETING ABSTRACT.

Ibarra-Lecue I, Pilar-Cuellar F, Muguruza C, Florensa-Zanuy E, Diaz A, Uriguen L, et al. The endocannabinoid system in mental disorders: Evidence from human brain studies. Biochem. Pharmacol.. 2018; 157: 97 - 107. FI: 4,235(Q1). DOI: 10.1016/j.bcp.2018.07.009. REVIEW.DOI:10.1016/j.ejmech.2017.06.008.

Ibi D, Revenga MD, Kezunovic N, Muguruza C, Saunders JM, Gaitonde SA, et al. Antipsychotic-induced Hdac2 transcription via NF-kappa B leads to synaptic and cognitive side effects. Nat Neurosci. 2017;20:1247. FI:17,839(Q1). DOI:10.1038/nn.4616.

Fernandez-Pastor B, Ortega JE, Grandoso L, Castro E, Ugedo L, Pazos A, et al. Chronic citalopram administration desensitizes prefrontal cortex but not somatodendritic a2-adrenoceptors in rat brain. Neuropharmacology. 2017;114:114-22. FI:5,012(Q1). DOI:10.1016/j.neuropharm.2016.11.025.

MacDowell KS, Munarriz-Cuezva E, Caso JR, Madrigal JL, Zabala A, Meana JJ, et al. Paliperidone reverts Toll-like receptor 3 signaling pathway activation and cognitive deficits in a maternal immune activation mouse model of schizophrenia. Neuropharmacology. 2017;116:196-207. FI:5,012(Q1). DOI:10.1016/j.neuropharm.2016.12.025.

Flood A, Trujillo C, Sanchez-Sanz G, Kelly B, Muguruza C, Callado LF, et al. Thiophene/thiazole-benzene replacement on guanidine derivatives targeting alpha(2)-Adrenoceptors. Eur J Med Chem. 2017;138:38-50. FI:4,519(Q1). DOI:10.1016/j.ejmech.2017.06.008.

Bioque M, Llerena A, Cabrera B, Mezquida G, Lobo A, Gonzáles-Pinto A, et al; PEPs GROUP. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. Int J Neuropsychopharmacol. 2016; 19:pyv121 . FI:4,712(Q1). DOI: 10.1093/ijnp/pyv121.

Diez-Alarcia R, Ibarra-Lecue I, Lopez-Cardona AP, Meana J, Gutierrez-Adan A, Callado LF, et al. Biased Agonism of Three Different Cannabinoid Receptor Agonists in Mouse Brain Cortex. Front Pharmacol. 2016;7:415 . FI:4,400(Q1). DOI: 10.3389/fphar.2016.00415.

Garcia-Bueno B, Gasso P, MacDowell KS, Callado LF, Mas S, Bernardo M, et al. Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia. J Psychiatry Neurosci. 2016;41:46-55. FI:5,165(Q1). DOI: 10.1503/jpn.150195.

Horrillo I, Ortega JE, Diez-Alarcia R, Uriguen L, Meana JJ. Effect of subchronic corticosterone administration on alpha(2)-adrenoceptor functionality in rat brain: an in vivo and in vitro study. Psychopharmacology. 2016;233:3861-7. FI:3,308(Q2). DOI: 10.1007/s00213-016-4418-3.

Mas S, Gassó P, Lafuente A, Bioque M, Lobo A, Gonzàlez-Pinto A, et al; PEPs GROUP. Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. Pharmacogenomics J. 2016;16: 439-45. FI:3,815(Q1). DOI: 10.1038/tpj.2016.44.

McMullan M, Garcia-Bea A, Miranda-Azpiazu P, Callado LF, Rozas I. Substituted conformationally restricted guanidine derivatives: Probing the alpha(2)-adrenoceptors' binding pocket. Eur J MeChem. 2016;123:48-57. FI:4,519(Q1). DOI: 10.1016/j.ejmech.2016.07.011.

Mezquida G, Penadés R, Cabrera B, Savulich G, Lobo A, González-Pinto A, et al. Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders. Eur Psychiat. 2016;38: 61-8. FI:3,123(Q2). DOI: 10.1016/j.eurpsy.2016.04.011.

Moreno JL, Miranda-Azpiazu P, Garcia-Bea A, Younkin J, Cui M, Kozlenkov A, et al. Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia. Sci Signal. 2016;9:ra5. FI:6,494(Q1). DOI: 10.1126/scisignal.aab0467.

Muguruza C, Meana JJ, Callado LF. Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs. Front Pharmacol. 2016;7:130. FI:4,400(Q1). DOI: 10.3389/fphar.2016.00130.

Pinacho R, Villalmanzo N, Meana JJ, Ferrer I, Berengueras A, Haro JM, et al. Altered CSNK1E, FABP4 and NEFH protein levels in the dorsolateral prefrontal cortex in schizophrenia. Schizophr Res. 2016;177:88-97. FI:3,986(Q1). DOI: 10.1016/j.schres.2016.04.050.

Rivero G, Martín-Guerrero I, de Prado E, Gabilondo AM, Callado LF, García-Sevilla JA, et al. Alpha2C-adrenoceptor Del322-325 polymorphism and risk of psychiatric disorders: significant association with opiate abuse and dependence. World J Biol Psychiatry. 2016;17:308-15. FI:3,658(Q2). DOI: 10.3109/15622975.2016.1142608.

Agirregoitia E, Ibarra-Lecue I, Totorikaguena L, Mendoza R, Exposito A, Matorras R, et al. Dynamics of expression and localization of the cannabinoid system in granulosa cells during oocyte nuclear maturation. Fertil Steril. 2015;104:753-760. FI:4,426(Q1). DOI:10.1016/j.fertnstert.2015.06.013.

Arteaga O, Revuelta M, Urigueen L, Alvarez A, Montalvo H, Hilario E. Pretreatment with Resveratrol Prevents Neuronal Injury and Cognitive Deficits Induced by Perinatal Hypoxia-Ischemia in Rats. PLoS One. 2015; 10:e014242. FI:3,057(Q1). DOI:10.1371/journal.pone.0142424.

Bustillo M, Querejeta I, Segarra R, Gonzalez-Pinto A, Alonso M, Mentxaka O, et al. Plasma levels of second generation antipsychotics as indicators of clinical response and severity of side-effects in first-episode psychosis patients. Eur Neuropsychopharm. 2015;25:513-514. FI:4,409(Q1). ABSTRACT

Bustillo M, Segarra R, Querejeta I, Gonzalez-Pinto A, Mentxaka O, Carton J, et al. Is therapeutic drug monitoring of olanzapine a useful clinical tool in first-episode psychosis patients?. Eur Neuropsychopharm. 2015;25:63-64. FI:4,409(Q1). ABSTRACT

Erdozain AM, Rubio M, Meana JJ, Fernandez-Ruiz, J, Callado LF. Altered CB1 receptor coupling to G-proteins in the post-mortem caudate nucleus and cerebellum of alcoholic subjects. J Psychopharmacol. 2015;29:1137-1145. FI:3,637(Q1). DOI:10.1177/0269881115599388.

Erdozain AM, Rubio M, Valdizan EM, Pazos A, Meana JJ, Fernández-Ruiz J, et al. The endocannabinoid system is altered in the post-mortem prefrontal cortex of alcoholic subjects. Addict Biol. 2015;20:773-783. FI:4,547(Q1). DOI:10.1111/adb.12160.

Gilabert-Juan J, Saez AR, Lopez-Campos G, Sebastia-Ortega N, Gonzalez-Martinez R, Costa J, et al. Semaphorin and plexin gene expression is altered in the prefrontal cortex of schizophrenia patients with and without auditory hallucinations. Psychiatry Res. 2015;229:850-857. FI:2,466(Q2). DOI:10.1016/j.psychres.2015.07.074.

Gil-Pisa I, Mollinedo Gajate I, Marmolejo S, Meana JJ, Gonzalez-Maeso J. Functional activity of the serotonin 5HT2A/MGLU2 receptors heterocomplex in mouse brain. Basic Clin Pharmacol. 2015;117:44. FI:3,097(Q2). ABSTRACT

Kelly B, McMullan M, Muguruza C, Ortega JE, Meana JJ, Callado LF, et al. Alpha(2)-Adrenoceptor Antagonists: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of Pyridinoguanidine, Pyridino-2-aminoimidazoline and Their Derivatives. J Med Chem. 2015;58:963-977. FI:5,589(Q1). DOI:10.1021/jm501635e.

Mollinedo-Gajate I, Gonzalez-Maeso J, Meana J. Functional interaction between serotonin 2A and metabotropic glutamate 2 receptors in the regulation of dopamine release in mouse prefrontal cortex. Eur Neuropsychopharm. 2015;25:261-262. FI:4,409(Q1). ABSTRACT

Mollinedo-Gajate I, Gonzalez-Maeso J, Meana JJ. Involvement of serotonin 2A-metabotropic glutamate 2 receptor heterocomplex in catecholamine release in mouse prefrontal cortex. Eur Neuropsychopharm. 2015;25:33-34. FI:4,409(Q1). ABSTRACT

Munarriz-Cuezva E, Prades R, Urigueen L, Royo S, Giralt E, Tarrago T, et al. The prolyl oligopeptidase inhibitor IPR19 improves cognitive deficits in schizophrenia-like mouse models. Eur Neuropsychopharm. 2015;25:479. FI:4,409(Q1). ABSTRACT

Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, Garcia-Sevilla JA. Adenosine A(1) receptors are selectively coupled to G alpha(i-3) in postmortem human brain cortex: Guanosine-5 `-O-(3-[S-35]thio)triphosphate ([S-35]GTP gamma S) binding/immunoprecipitation study. Eur J Pharmacol. 2015;764:592-598. FI:2,730(Q2). DOI:10.1016/j.ejphar.2015.07.049.

Pinacho R, Saia G, Meana JJ, Gill G, Ramos B. Transcription factor SP4 phosphorylation is altered in the postmortem cerebellum of bipolar disorder and schizophrenia subjects. Eur Neuropsychopharm. 2015;25:1650-1660. FI:4,409(Q1). DOI:10.1016/j.euroneuro.2015.05.006.

Prades R, Munarriza-Cuezva E, Urigueen L, Royo S, Giralt E, Meana J, et al. Selective prolyl oligopeptidase inhibition by IPR19 as a new pharmacological treatment of the cognitive impairment associated with schizophrenia. Eur Neuropsychopharm. 2015;25:479-480. FI:4,409(Q1). ABSTRACT

Rivero G, Gabilondo AM, Garcia-Sevilla JA, La Harpe R, Morentin B, Meana JJ. Up-regulated 14-3-3 beta and 14-3-3 zeta proteins in prefrontal cortex of subjects with schizophrenia: effect of psychotropic treatment. Schizophr Res. 2015;161:446-451. FI:4,453(Q1). DOI:10.1016/j.schres.2014.12.014.

Morentin B, Ballesteros J, Callado LF, Meana JJ. Recent cocaine use is a significant risk factor for sudden cardiovascular death in 15-49-year-old subjects: a forensic case-control study. Addiction. 2014;109:2071-8. FI: 4,738(Q1)

Muguruza C, Miranda-Azpiazu P, Díez-Alarcia R, Morentin B, González-Maeso J, Callado LF, et al. Evaluation of 5-HT2A and mGlu(2/3) receptors in postmortem prefrontal cortex of subjects with major depressive disorder: Effect of antidepressant treatment. Neuropharmacology. 2014;86:311-8. FI: 5,106(Q1)

Rivero G, Gabilondo AM, García-Sevilla JA, La Harpe R, Callado LF, Meana JJ. Increased alpha(2)- and beta(1)-adrenoceptor densities in postmortem brain of subjects with depression: Differential effect of antidepressant treatment. J Affect Disord. 2014;167:343-50. FI: 3,383(Q2)

García-Fuster MJ, Díez-Alarcia R, Ferrer-Alcón M, La Harpe R, Meana JJ, García-Sevilla JA. FADD adaptor and PEA-15/ERK1/2 partners in major depression and schizophrenia postmortem brains: basal contents and effects of psychotropic treatments. Neuroscience. 2014;277:541-51. FI: 3,357(Q2)

Gil-Pisa I, Cebrián C, Ortega JE, Meana JJ, Sulzer D. Cytokine pathway disruption in a mouse model of schizophrenia induced by Munc18-1a overexpression in the brain. J Neuroinflamm. 2014;11:128. FI: 5,408(Q1)

O'Donovan DH, Muguruza C, Callado LF, Rozas I. Guanidine-based alpha(2)-adrenoceptor ligands: Towards selective antagonist activity. Eur J Med Chem. 2014;82:242-54. FI: 3,447(Q1)

Erdozain AM, Morentin B, Bedford L, King E, Tooth D, Brewer C, et al. Alcohol-Related Brain Damage in Humans. PLoS One. 2014;9:e93586 . FI: 3,234(Q1)

Fernández-Fernández C, Callado LF, Girón R, Sánchez E, Erdozain AM, López-Moreno JA, et al. Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. Drug Des Dev Ther. 2014;8:263-77. FI: 3,028(Q2)

Meana JJ, Callado LF, Morentin B. Do post-mortem brain studies provide useful information for Psychiatry?. Rev Psiquiatr Salud Ment. 2014;7:101-3. FI: 1,622(Q3)

Gabilondo AM. Evaluation experience in research projects. Basic Clin Pharmacol Toxicol. 2014;115:3-4. FI: 2,377(Q2)

Erdozain AM, Callado LF. Neurobiological alterations in alcohol addiction: a review. Adicciones. 2014;26:360-70. FI: 1,154(Q4)

Ballesteros J, Guillen V, Zabala A, Santos B, Rueda JR, Sola I. Clinical outcomes in schizophrenia treated with donepezil in combination with antipsychotics. Value Health 2013;16:542. FI: 2,191(Q1). ( Meeting Abstract)

Fernández-Pastor B, Ortega JE, Meana JJ. Involvement of serotonin 5-HT3 receptors in the modulation of noradrenergic transmission by serotonin reuptake inhibitors: a microdialysis study in rat brain. Psychopharmacology. 2013;229:331-44. FI: 4,061(Q1)

Ormaza M, Fernandez L, Lafuente S, Corso M, Schiller F, Xu B, et al. LaAu2 and CeAu2 surface intermetallic compounds grown by high-temperature deposition on Au(111). Phys Rev B. 2013;88: -0. FI: 3,767(Q1)

Meana JJ. Agonist signal trafficking at serotonin 5-ht2a receptor in human brain: implications for schizophrenia and antipsychotic treatment. Basic Clin Pharmacol Toxicol. 2013;113:6. FI: 2,124(Q3). ( Meeting Abstract)

Meana JJ, Fernandez-Pastor B, Ortega JE, Grandoso L, Castro E, Ugedo L, et al. Chronic citalopram administration desensitizes prefrontal cortex but not somatodendritic a2-adrenoceptors in rat brain. Basic Clin Pharmacol Toxicol. 2013;113:17. FI: 2,124(Q3). ( Meeting Abstract)

Meana JJ, Miranda-Azpiazu P, Muguruza C, Diez-Alarcia R, Callado LF, Gonzalez-Maeso J. Different pharmacological properties of ketanserin and altanserin on serotonin 5-ht2a receptors in postmortem human brain: interest for schizophrenia studies. Basic Clin Pharmacol Toxicol. 2013;113:17-8. FI: 2,124(Q3). ( Meeting Abstract).

Muguruza C, Moreno JL, Umali A, Callado LF, Meana JJ, González-Maeso J. Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur Neuropsychopharmacol. 2013;23:852-64. FI: 4,595(Q1)

Muguruza C, Lehtonen M, Aaltonen N, Morentin B, Meana JJ, Callado LF. Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. Schizophr Res. 2013;148:145-50. FI: 4,590(Q1)

Pinacho R, Villalmanzo N, Roca M, Iniesta R, Monje A, Haro JM, et al. Analysis of Sp transcription factors in the postmortem brain of chronic schizophrenia: A pilot study of relationship to negative symptoms. J Psychiatr Res. 2013;47:926-34. FI: 4,066(Q1)

Ortega JE,  Gonzalez-Lira V, Horrillo I, Herrera-Marschitz M, Callado LF, Meana JJ. Additive effect of rimonabant and citalopram on extracellular serotonin levels monitored with in vivo microdialysis in rat brain. Eur J Pharmacol. 2013;709:13-9. FI: 2,592(Q2)

Ramos-Miguel A, Meana JJ, García-Sevilla JA. Cyclin-dependent kinase-5 and p35/p25 activators in schizophrenia and major depression prefrontal cortex: basal contents and effects of psychotropic medications. Int J Neuropsychopharmacol. 2013;16:683-9. FI: 5,641(Q1)

Ojeda N, Peña J, Bengoetxea E, García A, Sánchez P, Elizagárate E, et al. Evidence of the effectiveness of cognitive rehabilitation in psychosis and schizophrenia with the REHACOP programme Reply. Rev Neurol. 2013;56:400. FI: 1,179(Q4)

Rivero G, Gabilondo AM, García-Sevilla JA, Callado LF, La Harpe R, Morentin B, et al. Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment. Psychopharmacology. 2013;226:177-88. FI: 4,061(Q1)

Fernández-Fernández C, Decara J, Bermúdez-Silva FJ, Sánchez E, Morales P, Gómez-Cañas M, et al. Description of a Bivalent Cannabinoid Ligand with Hypophagic Properties. Arch Pharm. 2013;346:171-9. FI: 1,540(Q2)

Muguruza C, Rodríguez F, Rozas I, Meana JJ, Urigüen L, Callado LF. Antidepressant-like properties of three new alpha 2-adrenoceptor antagonists. Neuropharmacology. 2013;65:13-9. FI: 4,114(Q1)

Urigüen L, Gil-Pisa I, Munarriz-Cuezva E, Berrocoso E, Pascau J, Soto-Montenegro ML, et al. Behavioral, neurochemical and morphological changes induced by the overexpression of munc18-1a in brain of mice: relevance to schizophrenia. Transl Psychiatr. 2013;3:e221 FI: 0,000(Q0)

Alba-Delgado C, Llorca-Torralba M, Horrillo I, Ortega JE, Mico JA, Sánchez-Blázquez P, et al. Chronic Pain Leads to Concomitant Noradrenergic Impairment and Mood Disorders. Biol Psychiatry. 2013;73:54-62. FI: 9,247(Q1)

Tesis del grupo:

Autor/a: Daniel Betancor Pérez. Título: Estudio sobre identidad de género yRepresentaciones parentales. Directores: Dr. Juan Francisco Artaloytia Usobiaga, Dr. Rafael Segarra Echebarría.

Autor/a: Ohiane Mentxaka Solozabal. Título: Lehen pasarte psikotikoak eta delitu bortitzak: kausa ala mitoa? / Primeros episodios psicóticos y delitos violentos: ¿causa o mito?. Directores: Dr. Rafael Segarra Echebarria, Dr. Jon García Ormaza.

Autor/a: Jon García Ormaza. Título: Suicidio y desempleo: Barakaldo 2003-2014. Director/a: Dr. José Ignacio Eguiluz Uruchurtu, Dr. Rafael Segarra Echevarria. UPV/EHU

Autor/a: Mariana Bustillo Iceta. Título: Utilidad de la monitorización terapéutica de antipsicóticos de segunda generación en la práctica clínica de los primeros episodios psicóticos. Director/a: Dr. Rafael Segarra Echebarría, Dra. Arantzazu Zabala Rabadán. UPV/EHU

Autor/a: Eva Munarriz Cuezva. Título: Caracterización de las proteínas del complejo SNARE en esquizofrenia y su tratamiento. Director/a: Dra. Leyre Urigüen Echeverría, Dr. José Javier Meana Martínez. UPV/EHU

© 2021 IIS Biocruces Bizkaia